InvestSMART

Anatara Lifesciences Ltd (ASX:ANR)

ALERT: Price-sensitive ASX Announcement for ANR
Current share price for ANR : $0.010 -0.004 (-28.57%)+
Announcement
Release
30 Jan 2026 8:42AM
Price at Release
$0.014
Full Release
download
Summary
Anatara Lifesciences Ltd reported its quarterly activities for Q2 FY2026, highlighting progress in its Anti-Obesity Project with promising pre-clinical results from a compound named 'AOC'. The project faced delays in Mechanism of Action studies due to unavailable testing components, with final results expected soon. The company successfully raised $1.2 million via share placement and ended the quarter with $1.035 million in cash. Anatara remains focused on its strategic initiatives in the junior healthcare sector.
Key Points
  • Anatara Lifesciences Ltd (ASX:ANR) released its quarterly activities report for Q2 FY2026.
  • The report highlights the progress of the Anti-Obesity Project and GaRP project.
  • The Anti-Obesity Project involved pre-clinical studies on a compound 'AOC' showing promise in weight management.
  • There was a delay in the Mechanism of Action studies due to an international unavailability of a testing kit component.
  • The company managed to raise $1.2 million through a placement of shares.
  • Anatara reported cash reserves of $1.035 million at the end of December 2025.
  • The company continues to explore strategic directions and potential transactions in the healthcare sector.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.